With the advent of additional GLP-1 RAs, it is critical that the treatment landscape be monitored and reviewed so that healthcare practitioners have the most current information when addressing their patients needs
Bartalena L, Brogioni S, Grasso L, Velluzzi F, Martino E
Following discovery of a sparse number of occurrences of progressive multifocal leukoencephalopathy (PML) in those taking a FAE, median duration of FAE therapy to PML symptom onset or appearance of first PML brain lesion was 31 months (range 6110), with median duration of lymphocytopenia to PML symptoms being 23 months (range 672)
Flesch FM, Gadella BM
Third-party researchers combining lower doses with behavior change are seeing similar impact
Retrieved from Icken, D., Feller, S., Engeli, S., et al